(MENAFN- PR Newswire)
NEW YORK, Sept. 13, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape- The global exosome therapeutics market
size is estimated to grow by USD 234.7 million from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of
16.19%
during the forecast period. Increasing prevalence of chronic diseases
is driving market growth,
with a trend towards
advanced technology in exosome collection . However,
strict regulatory approval for exosome therpeutics launches
poses a challenge. Key market players include Aegle Therapeutics, Aethlon Medical Inc., AMS Biotechnology Europe Ltd., Bio Techne Corp., Capital Biosciences Inc., Capricor Therapeutics Inc., CILOA SAS, Creative Biolabs, Cytiva, Everzom, Evotec SE, Evox Therapeutics Ltd., ExoCoBio Co. Ltd., Inoviq Ltd., Lonza Group Ltd., NanoFCM Co., Ltd, Regeneron Pharmaceuticals Inc., ReNeuron Group plc, The ExoBiologics Co., and Thermo Fisher Scientific Inc..
Continue Reading
Technavio has announced its latest market research report titled Global exosome therapeutics market 2024-2028
Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report
| Exosome Therapeutics Market Scope |
| Report Coverage |
Details |
| Base year |
2023 |
| Historic period |
2018 - 2022 |
| Forecast period |
2024-2028 |
| Growth momentum & CAGR |
Accelerate at a CAGR of 16.19% |
| Market growth 2024-2028 |
USD 234.7 million |
| Market structure |
Fragmented |
| YoY growth 2022-2023 (%) |
15.76 |
| Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
| Performing market contribution |
North America at 30% |
| Key countries |
US, Germany, UK, China, and Japan |
| Key companies profiled |
Aegle Therapeutics, Aethlon Medical Inc., AMS Biotechnology Europe Ltd., Bio Techne Corp., Capital Biosciences Inc., Capricor Therapeutics Inc., CILOA SAS, Creative Biolabs, Cytiva, Everzom, Evotec SE, Evox Therapeutics Ltd., ExoCoBio Co. Ltd., Inoviq Ltd., Lonza Group Ltd., NanoFCM Co., Ltd, Regeneron Pharmaceuticals Inc., ReNeuron Group plc, The ExoBiologics Co., and Thermo Fisher Scientific Inc. |
Market Driver
The global exosome therapeutics market is experiencing significant growth due to advancements in exosome collection technologies. New methods, such as microfluidic devices, immunoaffinity capture, and continuous-flow systems, enable more efficient and effective exosome isolation and purification from complex samples. Microfluidic devices, in particular, provide high-throughput, efficient exosome isolation using techniques like deterministic lateral displacement and integrated immune isolation. These technologies manipulate small fluid volumes through microchannels with dimensions ranging from tens to hundreds of micrometers, offering unique functionality not previously possible with traditional methods. Additionally, nanoparticle tracking analysis (NTA) is used for exosome tracking in cancer research, determining concentration and size distribution of particles, further driving market growth.
Exosome Therapeutics is a rapidly growing field in healthcare, leveraging the transporting capacity of natural and hybrid exosomes for therapeutic applications. Exosomes derived from sources like Mesenchymal Stem Cells in Blood and Body Fluids, such as Urine, Saliva, Milk, and Dendritic Cells, are being explored for Immunotherapy, Chemotherapy, and Gene Therapy. Exosomes' small size and ability to carry Bio Macromolecules and Small Molecules make them promising for treating various disorders, including Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Inflammatory Disorders, Organ Transplantation, Gynecology Disorders, and Blood Disorders. Exosome-based Therapies are being developed for Parenteral and Oral administration. The market for Exosome Therapeutics and Exosome Diagnostics is expanding, with advancements in Exosome Isolation, Characterization, and Analysis. Companies are investing in technologies like Scale-X fixed-bed bioreactors and Extracellular Vesicles to improve Exosome production. Personalized medicine and FDA approvals for Gene Therapies and Cell-based Therapies are expected to fuel market growth. The aging population and the increasing prevalence of Chronic Wounds further boost demand.
Request Sample
of our comprehensive report now to stay ahead in the AI-driven market evolution!
Market Challenges
The regulatory approval process for exosome therapeutics is a significant challenge, with stringent regulations and unpredictable timelines. Exosomes used in clinical trials must adhere to Good Manufacturing Practices (GMP), with key issues being the upstream cell cultivation process, downstream purification process, and exosome quality control. Vendors must comply with regulatory requirements and provide safety and efficacy data during clinical trials. Japan has strict product approval guidelines in APAC, while technical challenges arise in other regions during the clinical trial phase. Failure to produce positive results in one region can burden vendors and negatively impact other trials, potentially hindering the growth of the global exosome therapeutics market.
The Exosome Therapeutics Market holds significant potential in addressing various health challenges, including chronic diseases like Alzheimer's, Parkinson's, and cancer. Exosomes, nanosized particles carrying genetic and protein cargo, offer a promising solution for molecular diagnosis and drug development. In the face of infectious diseases and autoimmune conditions, exosome technology can aid in immune suppression and precision medicine. Pharmaceutical and biopharmaceutical companies are increasingly investing in exosome research for drug therapies against neurodegeneration, cardiovascular dysfunction, and cancer. Key players in this field include Aethlon Medical. Exosome-based diagnostics, such as the ExoDx Prostate test and liquid biopsy, are revolutionizing cancer institutes and diagnostic centers. VA Healthcare System and instruments/software providers are also adopting this technology to enhance patient care. Despite these advancements, challenges persist in standardizing exosome isolation and characterization, as well as ensuring regulatory compliance.
Discover how AI is revolutionizing market trends-
Get your access now!
Segment Overview
This exosome therapeutics market report extensively covers market segmentation by
Application
1.1 Cancer therapies
1.2 Autoimmune diseases
1.3 Infectious diseases
1.4 Others
Distribution Channel
2.1 Hospital pharmacy
2.2 Retail pharmacy
2.3 Online pharmacy
Geography
3.1 North America
3.2 Europe
3.3 Asia
3.4 Rest of World (ROW)
1.1
Cancer therapies-
Exosomes are small vesicles released by cells that play a significant role in cancer progression, metastasis, immune response, and therapy resistance. In cancer therapy, exosomes act as drug transporters, offering novel strategies for targeted drug delivery. By loading exosomes with anticancer drugs or nucleic acids, precise targeting of cancer cells becomes possible, minimizing damage to healthy tissues. With cancer being a leading cause of mortality, such as the second most common cause in the US after heart disease, new cases reached around 1.9 million in the US and 20 million globally in 2023, resulting in approximately 9.7 million deaths. The increasing prevalence of cancer necessitates innovative therapies. Consequently, the growing cancer therapies segment is expected to fuel the expansion of the global exosome therapeutics market during the forecast period.
Download a Sample
of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics
Research Analysis
Exosome Therapeutics refer to the use of exosomes, small extracellular vesicles, as therapeutic agents for various diseases. Exosomes can be derived from natural sources such as body fluids like blood, urine, saliva, milk, and cultured cells like Mesenchymal Stem Cells and Dendritic Cells. Hybrid exosomes can be engineered to carry specific therapeutic cargos. Exosome-based therapeutics hold promise in immunotherapy, chemotherapy, and gene therapies for chronic diseases like cancer, autoimmune diseases, and infectious diseases. The market for Exosome Therapeutics and diagnostics is growing rapidly, with advancements in exosome isolation, characterization, and analysis using technologies like Scale-X fixed-bed bioreactors. Personalized medicine and FDA approvals are expected to further fuel market growth. Exosomes derived from different sources exhibit distinct characteristics and therapeutic potential, offering opportunities for targeted therapies and molecular diagnosis.
Market Research Overview
Exosome Therapeutics refers to the use of exosomes, small membrane-bound vesicles secreted by various cell types, as therapeutic agents. Exosomes carry bioactive molecules such as proteins, lipids, and nucleic acids, making them potential carriers for various therapeutic modalities. Exosomes can be derived from various sources, including Natural Exosomes from body fluids like blood, urine, saliva, milk, and Hybrid Exosomes produced through the fusion of donor cells and recipient cells. Exosome Therapeutics hold immense potential in various therapeutic areas such as Immunotherapy, Chemotherapy, and Gene Therapy. Their transporting capacity makes them effective in delivering bioactive molecules to target cells, making them promising candidates for treating Metabolic Disorders, Oncology, Cardiac Disorders, Neurology, Inflammatory Disorders, Organ Transplantation, and Gynecology Disorders. Exosome-based therapeutics are being developed using various techniques like Parenteral and Oral administration, and are being explored in Hospitals and Diagnostic Centers for Neurodegenerative Disorders, Chronic Wounds, and the Elderly Population. The Exosome diagnostics market is also growing, with applications in Molecular Diagnosis and Liquid Biopsy kits. Exosome isolation, characterization, and analysis are crucial steps in the Exosome value chain, and various techniques like Scale-X fixed-bed bioreactor, Ultracentrifugation, Precipitation, Chromatography, Differential centrifugation, Size-exclusion chromatography, and Immunoaffinity capture are used for this purpose. Exosomes have multifunctional properties and hold potential in treating Chronic Diseases, Infectious Diseases, and Autoimmune Diseases, including Cancer. FDA approvals for Exosome-based therapeutics and Gene therapies, as well as Cell-based therapies, are expected to drive the Exosome Therapeutics market. Exosome production is also a focus area for Pharmaceutical and Biopharmaceutical companies. Exosomes have emerged as a promising area of research due to their potential in Drug development and Drug therapies. The Exosome technology is being explored for its role in Precision medicine and Personalized medicine, making it a key area of interest for researchers and healthcare infrastructure.
Table of Contents:
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation
Application
Cancer Therapies
Autoimmune Diseases
Infectious Diseases
Others
Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Geography
North America
Europe
Asia
Rest Of World (ROW)
7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email:
[email protected]
Website:
SOURCE Technavio
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE?
440k+
Newsrooms &
Influencers
9k+
Digital Media
Outlets
270k+
Journalists
Opted In
GET STARTED
MENAFN13092024003732001241ID1108672311
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.